

Sunil Bhandari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2872394/publications.pdf>

Version: 2024-02-01

160
papers

12,582
citations

101543

36
h-index

31849

101
g-index

165
all docs

165
docs citations

165
times ranked

17500
citing authors

#	ARTICLE	IF	CITATIONS
1	The Impact of Intravenous Iron on Renal Injury and Function Markers in Patients With Chronic Kidney Disease and Iron Deficiency Without Anemia. <i>Kidney International Reports</i> , 2022, 7, 322-326.	0.8	2
2	Hypokalemia Events With Sodium Zirconium Cyclosilicate and Placebo in Hemodialysis Patients. <i>Kidney International Reports</i> , 2022, 7, 908-912.	0.8	0
3	Potassium responses to sodium zirconium cyclosilicate in hyperkalemic hemodialysis patients: post-hoc analysis of DIALIZE. <i>BMC Nephrology</i> , 2022, 23, 59.	1.8	5
4	The prevalence and potential aetiological factors associated with restless legs syndrome in patients with chronic kidney disease: a cross-sectional study. <i>International Urology and Nephrology</i> , 2022, , 1.	1.4	0
5	Dose effect analysis of sodium zirconium cyclosilicate in hemodialysis patients. <i>Hemodialysis International</i> , 2022, 26, 274-277.	0.9	1
6	Analysis of oxidative stress, inflammation and endothelial function following intravenous iron in chronic kidney disease in the Iron and Heart Trial. <i>Scientific Reports</i> , 2022, 12, 6853.	3.3	7
7	Acute interstitial nephritis after COVID-19 vaccination. <i>BMJ Case Reports</i> , 2022, 15, e246841.	0.5	10
8	Managing persistent hyperkalaemia with next-generation potassium binders. <i>Journal of Kidney Care</i> , 2022, 7, S1-S18.	0.1	0
9	Safety and efficacy of Iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 111-120.	0.7	61
10	Recent advances in drug discovery for diabetic kidney disease. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 447-461.	5.0	9
11	Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: The FERWON-NEPHRO trials. <i>American Journal of Hematology</i> , 2021, 96, E11-E15.	4.1	11
12	Improving the safety of intravenous iron treatments for patients with chronic kidney disease. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 23-35.	2.4	15
13	An evaluation of ferric derisomaltose as a treatment for anemia. <i>Expert Review of Hematology</i> , 2021, 14, 7-29.	2.2	5
14	The Prescription of intradialytic exercise to improve quality of Life in patients with chronic kidney disease trial: study design and baseline data for a multicentre randomized controlled trial. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1345-1355.	2.9	10
15	Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review. <i>Drugs in Context</i> , 2021, 10, 1-29.	2.2	19
16	The impact of e-alerts on inpatient diagnosis and management of acute kidney injury. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2021, 82, 1-11.	0.5	1
17	Age, Gender and Diabetes as Risk Factors for Early Mortality in Dialysis Patients: A Systematic Review. <i>Clinical Medicine and Research</i> , 2021, 19, 54-63.	0.8	2
18	A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 67 functional status. <i>BMC Nephrology</i> , 2021, 22, 115.	1.8	15

#	ARTICLE	IF	CITATIONS
19	The comparative effects of intravenous iron on oxidative stress and inflammation in patients with chronic kidney disease and iron deficiency: a randomized controlled pilot study. <i>Kidney Research and Clinical Practice</i> , 2021, 40, 89-98.	2.2	11
20	Point-of-care testing technologies for the home in chronic kidney disease: a narrative review. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2316-2331.	2.9	15
21	MO201 ANALYSIS OF USAGE OF SODIUM ZIRCONIUM CYCLOSILICATE (SZC) AT HULL UNIVERSITY TEACHING HOSPITALS. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
22	FC 096 THE EFFECT OF INCREMENTAL START OF HAEMODIALYSIS ON BLOOD PRESSURE AND INTERDIALYTIC WEIGHT GAIN: PRELIMINARY FINDINGS FROM THE ENDURE STUDY. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
23	Safety and Efficacy of Intravenous Ferric Derisomaltose Compared to Iron Sucrose for Iron Deficiency Anemia in Patients with Chronic Kidney Disease With and Without Heart Failure. <i>American Journal of Cardiology</i> , 2021, 152, 138-145.	1.6	11
24	A mixed-method feasibility study of a novel transitional regime of incremental haemodialysis: study design and protocol. <i>Clinical and Experimental Nephrology</i> , 2021, 25, 1131-1141.	1.6	3
25	Exercise programme to improve quality of life for patients with end-stage kidney disease receiving haemodialysis: the PEDAL RCT. <i>Health Technology Assessment</i> , 2021, 25, 1-52.	2.8	19
26	Heart Failure Hospitalization in Adults Receiving Hemodialysis and the Effect of Intravenous Iron Therapy. <i>JACC: Heart Failure</i> , 2021, 9, 518-527.	4.1	9
27	Randomized Trial of Prescription of Intradialytic Exercise to Improve Quality of Life in Patients Receiving Hemodialysis. <i>Kidney International Reports</i> , 2021, 6, 2159-2170.	0.8	22
28	Reasons for COVID-19 vaccination hesitancy in hemodialysis patients. <i>Kidney International</i> , 2021, 100, 702.	5.2	4
29	Stroke in hemodialysis patients randomized to different intravenous iron strategies: a prespecified analysis from the PIVOTAL trial. <i>Kidney360</i> , 2021, 2, 10.34067/KID.0004272021.	2.1	7
30	The effect of digoxin on renal function in patients with heart failure. <i>BMC Nephrology</i> , 2021, 22, 349.	1.8	3
31	Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2020, 97, 42-61.	5.2	260
32	Elasto-Plastic Finite Element Modeling of Short Carbon Fiber Reinforced 3D Printed Acrylonitrile Butadiene Styrene Composites. <i>Jom</i> , 2020, 72, 475-484.	1.9	12
33	Early Mortality Rates After Commencement of Maintenance Hemodialysis: A Systematic Review and Meta-Analysis. <i>Therapeutic Apheresis and Dialysis</i> , 2020, 24, 275-284.	0.9	7
34	The role of patient portals in enhancing self-care in patients with renal conditions. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 1-7.	2.9	14
35	Getting the basics right: the monitoring of arteriovenous fistulae, a review of the evidence. <i>Current Opinion in Nephrology and Hypertension</i> , 2020, 29, 564-571.	2.0	2
36	Discrete-Event Simulation Thermal Model for Extrusion-Based Additive Manufacturing of PLA and ABS. <i>Materials</i> , 2020, 13, 4985.	2.9	13

#	ARTICLE	IF	CITATIONS
37	Hypochloraemia in Patients with Heart Failure: Causes and Consequences. <i>Cardiology and Therapy</i> , 2020, 9, 333-347.	2.6	22
38	P0858A MULTICENTRE PROSPECTIVE DOUBLE BLIND RANDOMISED CONTROLLED TRIAL OF INTRAVENOUS IRON IN IRON DEFICIENT BUT NOT ANAEMIC PATIENTS WITH CHRONIC KIDNEY DISEASE ON FUNCTIONAL STATUS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	1
39	P0851THE DIFFERENTIAL IMPACT OF INTRAVENOUS IRON IN A MODEL OF EXPERIMENTAL URAEMIA ON TISSUE MARKERS OF OXIDATIVE STRESS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
40	SO051PROSPECTIVE OPEN-LABEL EXPLORATIVE RANDOMISED SINGLE CENTRE COMPARATIVE STUDY TO DETERMINE THE EFFECTS OF VARIOUS INTRAVENOUS IRON PREPARATIONS ON HAEMOGLOBIN, HAEMETENICS, MARKERS OF KIDNEY FUNCTION, QUALITY OF LIFE AND SAFETY. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
41	Measurement of Glutathione as a Tool for Oxidative Stress Studies by High Performance Liquid Chromatography. <i>Molecules</i> , 2020, 25, 4196.	3.8	32
42	NIMO-CKD-UK: a real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease. <i>BMC Nephrology</i> , 2020, 21, 539.	1.8	10
43	MO016MYOCARDIAL INFARCTION IN THE PIVOTAL STUDY OF IV IRON IN HAEMODIALYSIS: A PRE-SPECIFIED SECONDARY ANALYSIS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
44	P0331ASSESSMENT OF DELIVERY OF NICE APPROVED USE OF TOLVAPTAN (JINARC) IN ADULTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE IN A UK RENAL CENTRE. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	1
45	P0848PROSPECTIVE OPEN-LABEL EXPLORATIVE RANDOMISED SINGLE-CENTRE COMPARATIVE STUDY TO DETERMINE THE EFFECTS OF VARIOUS INTRAVENOUS IRON PREPARATIONS ON MARKERS OF OXIDATIVE STRESS AND KIDNEY INJURY IN CHRONIC KIDNEY DISEASE (IRON-CKD). <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
46	Conversion of haemodialysis patients from iron sucrose to iron isomaltoside: a real-world experience. <i>BMC Nephrology</i> , 2020, 21, 212.	1.8	3
47	A 6 month extension trial evaluating safety and efficacy of ferric derisomaltose in patients with iron deficiency anemia: The <sc>FERWONâ€EXT</sc> trial. <i>American Journal of Hematology</i> , 2020, 95, E276.	4.1	6
48	MO015HAEMODIALYSIS VASCULAR ACCESS THROMBOSIS: AN ANALYSIS OF EVENTS FROM THE PROACTIVE IV IRON THERAPY IN HAEMODIALYSIS PATIENTS (PIVOTAL) TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
49	Protocol and Baseline Data of a Multicentre Prospective Double-Blinded Randomized Study of Intravenous Iron on Functional Status in Patients with Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2020, 51, 493-500.	3.1	8
50	Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis: A Prespecified Secondary Analysis of the PIVOTAL Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1118-1127.	6.1	55
51	Falling Usage of Hospital-Based Emergency Care during the Covid-19 Pandemic in the Uk. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2020, 50, 210-212.	0.6	3
52	Enhancing the interlayer tensile strength of 3D printed short carbon fiber reinforced PETG and PLA composites via annealing. <i>Additive Manufacturing</i> , 2019, 30, 100922.	3.0	117
53	How Do We Navigate the Complexities Surrounding the Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Chronic Kidney Disease?. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2166-2169.	3.0	8
54	Impact of Intravenous Iron on Oxidative Stress and Mitochondrial Function in Experimental Chronic Kidney Disease. <i>Antioxidants</i> , 2019, 8, 498.	5.1	17

#	ARTICLE	IF	CITATIONS
55	A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1723-1733.	6.1	100
56	Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD). <i>Trials</i> , 2019, 20, 194.	1.6	4
57	Safety of Intravenous Iron “Cosmofer and Monofer Therapy in Peritoneal Dialysis and Non-Dialysis-Dependent Chronic Kidney Disease Patients. <i>Peritoneal Dialysis International</i> , 2019, 39, 192-195.	2.3	15
58	Can incremental haemodialysis reduce early mortality rates in patients starting maintenance haemodialysis?. <i>Current Opinion in Nephrology and Hypertension</i> , 2019, 28, 641-647.	2.0	11
59	Finite element modeling of 3D-printed part with cellular internal structure using homogenized properties. <i>Progress in Additive Manufacturing</i> , 2019, 4, 143-154.	4.8	14
60	Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. <i>New England Journal of Medicine</i> , 2019, 380, 447-458.	27.0	321
61	ACE inhibitors and ARBs: Managing potassium and renal function. <i>Cleveland Clinic Journal of Medicine</i> , 2019, 86, 601-607.	1.3	32
62	The safety of available treatment options for iron-deficiency anemia. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 149-159.	2.4	45
63	Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data. <i>American Journal of Nephrology</i> , 2018, 48, 260-268.	3.1	30
64	Oxidative Stress and Cardiovascular Complications in Chronic Kidney Disease, the Impact of Anaemia. <i>Pharmaceuticals</i> , 2018, 11, 103.	3.8	39
65	Intravenous Irons: From Basic Science to Clinical Practice. <i>Pharmaceuticals</i> , 2018, 11, 82.	3.8	55
66	Finite element analysis of thermoplastic polymer extrusion 3D printed material for mechanical property prediction. <i>Additive Manufacturing</i> , 2018, 22, 187-196.	3.0	35
67	A systematic review of known interventions for the treatment of chronic nonhypovolaemic hypotonic hyponatraemia and a meta-analysis of the vaptans. <i>Clinical Endocrinology</i> , 2017, 86, 761-771.	2.4	36
68	Anemia in Peritoneal Dialysis Patients; Iron Repletion, Current and Future Therapies. <i>Peritoneal Dialysis International</i> , 2017, 37, 6-13.	2.3	13
69	Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1530-1539.	0.7	38
70	Renal function after new treatment with renin-angiotensin system blockers. <i>BMJ: British Medical Journal</i> , 2017, 356, j1122.	2.3	3
71	The Use of Automated Electronic Alerts in Studying Short-Term Outcomes Associated with Community-Acquired Acute Kidney Injury. <i>Nephron</i> , 2017, 135, 181-188.	1.8	6
72	ORAI channels are critical for receptor-mediated endocytosis of albumin. <i>Nature Communications</i> , 2017, 8, 1920.	12.8	39

#	ARTICLE	IF	CITATIONS
73	Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC Nephrology, 2017, 18, 345.	1.8	179
74	Current misconceptions in diagnosis and management of iron deficiency. Blood Transfusion, 2017, 15, 422-437.	0.4	83
75	Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial. Nephrology Dialysis Transplantation, 2016, 31, gfv346.	0.7	81
76	SP321SAFETY OF IV IRON THERAPY IN CHRONIC KIDNEY DISEASE PATIENTS. Nephrology Dialysis Transplantation, 2016, 31, i197-i197.	0.7	9
77	Efficacy and safety of iron isomaltoside (Monofer®) in the management of patients with iron deficiency anemia. International Journal of Nephrology and Renovascular Disease, 2016, 9, 53.	1.8	43
78	SP537EVALUATION OF THE TRAINING RECEIVED BY RENAL TRAINEES IN DIALYSIS LINE INSERTION. Nephrology Dialysis Transplantation, 2016, 31, i271-i272.	0.7	0
79	Safety of intravenous iron use in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2016, 25, 529-535.	2.0	44
80	Should We STOP Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Advanced Kidney Disease?. Nephron, 2016, 133, 147-158.	1.8	8,212
81	Barriers to patient participation in a self-management and education website Renal PatientView: A questionnaire-based study of inactive users. International Journal of Medical Informatics, 2016, 87, 10-14.	3.3	16
82	A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrology Dialysis Transplantation, 2016, 31, 646-655.	0.7	70
83	The Impact of Lowering Haemoglobin Targets on Patterns of Erythropoiesis-Stimulating Agent Use in Patients on Haemodialysis. Blood Purification, 2016, 41, 287-292.	1.8	4
84	Renal Squamous Cell Carcinoma of a Native Kidney After Renal Transplant: A Case Report. Transplantation Proceedings, 2016, 48, 259-261.	0.6	8
85	Correction of iron deficiency anaemia using IV CosmoFer in CKD patients with asthma: a prospective study. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 187-190.	0.5	2
86	Arterio-Venous Fistula: Is it Critical for Prolonged Survival in the over 80's Starting Haemodialysis?. PLoS ONE, 2016, 11, e0163487.	2.5	6
87	Data confusion. Kidney International, 2015, 88, 1445.	5.2	6
88	A randomized, open-label trial of iron isomaltoside 1000 (MonoferÂ®) compared with iron sucrose (VenoferÂ®) as maintenance therapy in haemodialysis patients. Nephrology Dialysis Transplantation, 2015, 30, 1577-1589.	0.7	60
89	Examining Determinants of Patient Outcome in a Low Clearance Clinic. Nephron, 2015, 129, 263-268.	1.8	2
90	High glucose enhances store-operated calcium entry by upregulating ORAI/STIM via calcineurin-NFAT signalling. Journal of Molecular Medicine, 2015, 93, 511-521.	3.9	45

#	ARTICLE	IF	CITATIONS
91	Mitochondrial dysfunction in uremic cardiomyopathy. American Journal of Physiology - Renal Physiology, 2015, 308, F579-F587.	2.7	34
92	Cathasept Line Lock and Microbial Colonization of Tunneled Hemodialysis Catheters: A Multicenter Randomized Controlled Trial. American Journal of Kidney Diseases, 2015, 66, 1015-1023.	1.9	28
93	Case Report: Guillain-Barre Syndrome following Renal Transplantation - A Diagnostic Dilemma. Nephron Clinical Practice, 2014, 124, 239-242.	2.3	8
94	Deferiprone, iron overload in a renal transplant patient. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 465-466.	0.5	4
95	Analysis of factors predicting mortality of new patients commencing renal replacement therapy 10 years of follow-up. BMC Nephrology, 2014, 15, 20.	1.8	18
96	Correlation of Iron Overload and Glomerular Filtration Rate Estimated by Cystatin C in Patients with β -Thalassemia Major. Hemoglobin, 2014, 38, 365-368.	0.8	10
97	Happy, "healthy" and enjoying life on dialysis: an elderly perspective. International Urology and Nephrology, 2014, 46, 1035-1036.	1.4	1
98	Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol. Transplantation Research, 2013, 2, 7.	1.5	21
99	Investigating polyuria. BMJ, The, 2013, 347, f6772-f6772.	6.0	2
100	State of the iron: How to diagnose and efficiently treat iron deficiency anemia in inflammatory bowel disease. Journal of Crohn's and Colitis, 2013, 7, 429-440.	1.3	71
101	Case Report: Crohn's-like Mycophenolate-Induced Colitis, a Fallout in Steroid-Free Regimens. Transplantation Proceedings, 2013, 45, 842-844.	0.6	12
102	Iron (III) isomaltoside 1000. Expert Review of Hematology, 2013, 6, 239-246.	2.2	9
103	South Asian hospitals that lack DNAR orders deny patients holistic care. BMJ, The, 2013, 347, f6300-f6300.	6.0	1
104	The prevalence of potentially inappropriate medication prescribing in elderly patients with chronic kidney disease. Postgraduate Medical Journal, 2013, 89, 247-250.	1.8	60
105	Side effects of Deferasirox Iron Chelation in Patients with Beta Thalassemia Major or Intermedia. Oman Medical Journal, 2013, 28, 121-124.	1.0	38
106	Uremic cardiomyopathy is characterized by loss of the cardioprotective effects of insulin. American Journal of Physiology - Renal Physiology, 2012, 303, F1275-F1286.	2.7	8
107	Determinants and Consequences of Renal Function Variations With Aldosterone Blocker Therapy in Heart Failure Patients After Myocardial Infarction. Circulation, 2012, 125, 271-279.	1.6	136
108	U-shaped effect of eGFR and mortality. Kidney International, 2012, 81, 1152.	5.2	1

#	ARTICLE	IF	CITATIONS
109	Aldosterone blockade: the heart versus the kidney. <i>Kidney International</i> , 2012, 82, 1136.	5.2	0
110	Value of Carnitine Therapy in Kidney Dialysis Patients and Effects on Cardiac Function from Human and Animal Studies. <i>Current Drug Targets</i> , 2012, 13, 285-293.	2.1	12
111	Interpreting and investigating proteinuria. <i>BMJ, The</i> , 2012, 344, e2339-e2339.	6.0	4
112	Deferasirox and renal dysfunction in children. <i>Pediatric Nephrology</i> , 2012, 27, 2159-2159.	1.7	4
113	Renal aspects of thalassaemia a changing paradigm. <i>European Journal of Haematology</i> , 2012, 89, 187-197.	2.2	42
114	Iron therapy in patients with chronic kidney disease. <i>Transfusion Alternatives in Transfusion Medicine</i> , 2012, 12, 115-121.	0.2	4
115	Beyond efficacy and safety--the need for convenient and cost-effective iron therapy in health care. <i>CKJ: Clinical Kidney Journal</i> , 2011, 4, i14-i19.	2.9	6
116	Risk factors and metabolic mechanisms in the pathogenesis of uraemic cardiac disease. <i>Frontiers in Bioscience - Landmark</i> , 2011, 16, 1364.	3.0	20
117	Update of a comparative analysis of cost minimization following the introduction of newly available intravenous iron therapies in hospital practice. <i>Therapeutics and Clinical Risk Management</i> , 2011, 7, 501.	2.0	40
118	A hospital-based cost minimization study of the potential financial impact on the UK health care system of introduction of iron isomaltoside 1000. <i>Therapeutics and Clinical Risk Management</i> , 2011, 7, 103.	2.0	18
119	Uremic Cardiomyopathy and Insulin Resistance. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 207-215.	6.1	57
120	Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease. <i>Journal of Nephrology</i> , 2011, 24, 589-596.	2.0	44
121	Prevalence of modifiable cardiovascular risk factors in long-term renal transplant patients. <i>International Journal of Nephrology and Renovascular Disease</i> , 2010, 3, 175.	1.8	3
122	Functional and metabolic adaptation in uraemic cardiomyopathy. <i>Frontiers in Bioscience - Elite</i> , 2010, E2, 1492-1501.	1.8	9
123	Influence of Intravenous Iron Therapy on Novel Markers of Iron Deficiency. <i>International Journal of Artificial Organs</i> , 2010, 33, 297-301.	1.4	5
124	The effect of spontaneous twin pregnancy on renal transplant function and haemodynamics. <i>CKJ: Clinical Kidney Journal</i> , 2010, 3, 48-50.	2.9	3
125	The Effect of Iron and Erythropoietin Treatment on the A1C of Patients With Diabetes and Chronic Kidney Disease. <i>Diabetes Care</i> , 2010, 33, 2310-2313.	8.6	93
126	Counselling Prior to Blood-Borne Virus Screening in Haemodialysis Patients: A Survey of Patient Experience and Opinion. <i>Nephron Clinical Practice</i> , 2009, 112, c94-c97.	2.3	2

#	ARTICLE	IF	CITATIONS
127	Cellular basis of uraemic cardiomyopathy: a role for erythropoietin?. European Journal of Heart Failure, 2009, 11, 732-738.	7.1	14
128	Perspectives on eGFR reporting from the Interface between Primary and Secondary Care. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 258-260.	4.5	6
129	Insulin resistance and altered glucose transporter 4 expression in experimental uremia. Kidney International, 2009, 75, 711-718.	5.2	16
130	Photopheresis therapy for problematic renal allograft rejection. Journal of Clinical Apheresis, 2009, 24, 161-169.	1.3	19
131	The Effects of Angiotensin Converting Enzyme Inhibitors on Potassium Homeostasis in Dialysis Patients With and Without Residual Renal Function. Artificial Organs, 2009, 33, 641-647.	1.9	18
132	Effect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantation. Transplant International, 2009, 22, 821-830.	1.6	34
133	A single-centre audit of junior doctors' diagnostic activity in medical admissions. Journal of the Royal College of Physicians of Edinburgh, The, 2009, 39, 307-312.	0.6	8
134	Improving efficiency and value in health care—Intravenous iron management for anaemia associated with chronic kidney disease: linking treatment to an outpatient clinic, optimizing service provision and patient choice. Journal of Evaluation in Clinical Practice, 2008, 14, 996-1001.	1.8	22
135	Safety of Outpatient Kidney Biopsy: One Center'S Experience With 178 Native Kidney Biopsies. American Journal of Kidney Diseases, 2008, 52, 631-632.	1.9	10
136	THE USE OF PHARMACEUTICALS FOR DIALYSIS PATIENTS. HOW WELL DO WE KNOW OUR PATIENTS' ALLERGIES?. Journal of Renal Care, 2008, 34, 213-217.	1.2	3
137	Mortality at Low and High Estimated Glomerular Filtration Rate Values: A U Shaped Curve. Nephron Clinical Practice, 2008, 110, c67-c72.	2.3	47
138	Expression of Somatostatin and Somatostatin Receptor Subtypes 1-5 in Human Normal and Diseased Kidney. Journal of Histochemistry and Cytochemistry, 2008, 56, 733-743.	2.5	61
139	Effects of applying a standardised management algorithm for moderate to severe renal dysfunction in patients with chronic stable heart failure. European Journal of Heart Failure, 2007, 9, 415-423.	7.1	22
140	Myocardial Function, Energy Provision, and Carnitine Deficiency in Experimental Uremia. Journal of the American Society of Nephrology: JASN, 2007, 18, 84-92.	6.1	26
141	Tolerability and efficacy of parenteral iron therapy in hemodialysis patients, a comparison of preparations. Transfusion Alternatives in Transfusion Medicine, 2007, 9, 37-42.	0.2	46
142	Bolus intraperitoneal iron versus intravenous iron in peritoneal dialysis patients: a prospective study. Transfusion Alternatives in Transfusion Medicine, 2007, 9, 101-107.	0.2	3
143	Epidemiology, Associated Factors, and Prognostic Outcomes of Renal Artery Stenosis in Chronic Heart Failure Assessed by Magnetic Resonance Angiography. American Journal of Cardiology, 2007, 100, 273-279.	1.6	58
144	Acute interstitial nephritis induced by glucosamine. Nephrology Dialysis Transplantation, 2006, 21, 2031-2031.	0.7	8

#	ARTICLE	IF	CITATIONS
145	Anemia, Renal Dysfunction, and Their Interaction in Patients With Chronic Heart Failure. American Journal of Cardiology, 2006, 98, 391-398.	1.6	125
146	Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. European Heart Journal, 2006, 27, 569-581.	2.2	203
147	Clarithromycin-induced granulomatous tubulointerstitial nephritis. Nephrology Dialysis Transplantation, 2006, 21, 2654-2655.	0.7	11
148	Atherosclerotic renovascular disease in chronic heart failure: should we intervene?. European Heart Journal, 2005, 26, 1596-1605.	2.2	48
149	The man who gained a stone. Nephrology Dialysis Transplantation, 2003, 18, 434-435.	0.7	6
150	Carcinoma of the bronchus presenting as renal failure secondary to amyloidosis. Nephrology Dialysis Transplantation, 2003, 18, 1031-1031.	0.7	6
151	Influences of the N- and C-Termini of the Distal Nephron Inward Rectifier, ROMK. Kidney and Blood Pressure Research, 2001, 24, 142-148.	2.0	3
152	Surgical Correction of Nephrotic Syndrome. Nephron, 2001, 87, 291-292.	1.8	7
153	Biophysical effects of pore mutations of ROMK1. Clinical Science, 2001, 101, 121.	4.3	1
154	RACK1: a putative inward rectifier potassium channel of the distal nephron. Investigation in Xenopus laevis oocytes. Nephrology, 2001, 6, 285-289.	1.6	0
155	INCREASED CAESIUM SENSITIVITY OF ROMK1 BY MUTATIONS OF THE PORE RESIDUE GLYCINE 143 (G143). Nephrology, 2000, 5, A110-A110.	1.6	0
156	KARYOMEGALIC NEPHROPATHY A RARE CAUSE OF RENAL FAILURE â€•HLA AND PLOIDY ANALYSIS. Nephrology, 2000, 5, A109-A109.	1.6	0
157	INCREASED BARIUM SENSITIVITY OF ROMK1 BY POINT MUTATIONS OF GLYCINE 143. Nephrology, 2000, 5, A100-A100.	1.6	0
158	Evaluation of RBC ferritin and reticulocyte measurements in monitoring response to intravenous iron therapy. American Journal of Kidney Diseases, 1997, 30, 814-821.	1.9	44
159	Atherosclerotic renovascular disease in the elderly: angioplasty with stenting versus reconstructive surgery. Geriatric Nephrology and Urology, 1997, 7, 87-94.	0.3	4
160	Lesson of the week: Man's best friend: life threatening sepsis after minor dog bite. BMJ: British Medical Journal, 1997, 314, 129-129.	2.3	20